Hints and tips:
Related Special Reports
...After the latter was bought by Swiss pharmaceutical group Roche in 2009, he rose through the ranks, becoming Genentech’s chief executive in 2017 and Roche’s head of pharma two years later....
...Roche said it was also reviewing its manufacturing operations to improve efficiency. It recently sold a large site in California to contract manufacturer Lonza for $1.2bn....
...The Swiss group made SFr58.7bn ($68bn) in 2023, a 7 per cent decline from SFr63.2bn in 2022 and below analysts’ estimates....
...(Stephanie Kelton) — The Fed takes a look at private credit (Fed Reserve) — Scenes From the Bat Cave (American Prospect) — AI art vs real life (X) — The secret payments behind the deal that brought Chad...
...Voters in Chad have approved a new constitution that authorities say will usher in an era of democratic rule even as the referendum was marred by opposition boycotts and allegations that it was a fix....
...Barclays estimates the market could be worth $100bn within a decade, Switzerland’s Roche has just boosted its chances of being a contender....
...Roche is to acquire Carmot Therapeutics for up to $3.1bn, in the industry’s latest significant investment in the booming obesity treatment market....
...That holds true for pharmaceutical companies which are looking a bit peaky. Roche, whose stock has fallen 27 per cent in the past 12 months, is a case in point....
...Roche first tried to develop a drug using GLP-1s more than a decade ago, before ditching the attempt....
...Roche will pay $7.1bn upfront and a near term milestone payment of $150mn. Roivant owns 75 per cent of Telavant, while Pfizer owns 25 per cent....
...Roche will pay $7.1bn upfront and a near-term milestone payment of $150mn. Pfizer will keep the commercialisation rights outside the US and Japan....
...Roche is therefore acquiring US-based obesity drugs developer Carmot for up to $3.1bn. The Swiss company already has a packed pipeline. The problem is that too many drug trials have failed....
...Roche has inadvertently disclosed positive results from a closely watched lung cancer drug study, sending shares in the Swiss pharma group up as much as 5 per cent....
...Déby is supposed to be France’s last ally in the Sahel and Chad is a pillar of the fight against terrorism in the region. For France, the former colonial power, it has been a humbling experience....
...Sanofi trades on a forward price/earnings ratio of 11 times, Roche on 12.4 times and Novartis on 14.5 times. By comparison, obesity drugs developer Novo Nordisk trades on 33.6 times....
...It’s a tremendous paradox of our age.”...
...Consider how Roche spent its cash. It acquired obesity drug developer Carmot Therapeutics for $2.7bn....
...The crunchy acronym was coined by Goldman Sachs for pharma companies GSK and Roche, Dutch chip company ASML, Switzerland’s Nestlé and Novartis, Danish drugmaker Novo Nordisk, France’s L’Oréal and LVMH, the...
...Roche is conducting phase 1 clinical trials in humans on the candidate drug, which targets a bacterium known as carbapenem-resistant Acinetobacter baumannii, or CRAB....
...The controversy in Togo comes at a time of democratic backsliding across west and central Africa, a region that has witnessed eight successful coups in Mali, Guinea, Burkina Faso, Chad, Niger and Gabon since...
...Lewis, a forceful musical presence, needs the balance of drummer Chad Taylor’s hefty rimshot whacks and the off-kilter loose-skinned rolls that he delivers so powerfully....
...Just look at Roche (down 15.8 per cent in 2023, and a further 4.6 per cent year-to-date in 2024) and Nestlé (down 9 per cent and 5.1 per cent over the same periods)....
...An independent panel of experts that compiled a report for the UN said there was strong evidence the UAE was supplying arms in the guise of humanitarian supplies through Chad....
...EU summit: EU leaders will convene in an attempt to reach a deal on a €50bn support package for Ukraine....
...“Chad is a wall for the Sahel,” he said....
International Edition